Massachusetts General Hospital
Boston, MA
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Maintenance Trials
Only view trials that include maintenance therapy.
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Not yet accepting
SUCCESSOR-1
Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- CELMoD
- Randomization
- Phase 3
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
STOMP
Phase 1B / 2 Study of Selinexor in Combination With Other Treatments for Relapsed/Refractory and Newly Diagnosed Multiple Myeloma.
- CELMoD
- SINE
- Phase 1/2
- Has results
Accepting patients
Bone Marrow & Kidney Transplant
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)
- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Daratumumab Combination Therapy
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- Monoclonal Antibody
- Proteasome Inhibitor
- CD38
- Phase 2
- CAR T Cell
- APRIL
- BCMA
- Phase 1
Accepting patients
ISABELA
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
- Monoclonal Antibody
- CD38
- Quadruplet Therapy
- Phase 2
Accepting patients
CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 3
Accepting patients
Elranatamab as Consolidation
A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- CD3
- Phase 2
Accepting patients
iMMAGINE-1
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- Phase 2
- Has results
3 hidden based on your filters. Show All